IDNA News and Press, iShares Genomics Immunology and Healthcare From 01/09/20

The new budget proposed by California Governor Gavin Newsom includes a plan to allow the state to contract with generic drug makers to provide medicines to all Californians. He believes that the government's purchasing power may be sufficient to cut drug prices to the state's 40M residents...

Results from a new study showed that end-of-year drug approvals by the FDA are linked to more hospitalizations, life-threatening events and deaths, a rate about twice as high as medicines approved earlier in the year. More news on: ProShares Trust - ProShares Ultra Nasdaq Biotechnology,...

Reuters reports that pharmaceutical companies, including Pfizer (NYSE: PFE ), GlaxoSmithKline (NYSE: GSK ) and Sanofi (NASDAQ: SNY ), are planning to raise prices on more than 200 medicines in the U.S. tomorrow. More news on: Pfizer Inc., GlaxoSmithKline plc, Sanofi, Healthcare stocks ne...

The Institute for Clinical and Economic Review (ICER), a Boston-based nonpartisan nonprofit with no policy-making role, has emerged as a major influencer on pricing by drugmakers. More news on: Sanofi, Regeneron Pharmaceuticals, Inc., Amgen Inc., Healthcare stocks news, News on ETFs, ...

In a statement , the FDA says chronic shortages of certain medicines in the U.S. have not produced the expected responses from drugmakers that traditional economics predict, specifically, increasing prices to reflect a supply/demand imbalance aimed at achieving profitable production to sati...

On a strict party line basis, the U.S. House of Representatives' Education and Labor Committee voted 27-21 backing Speaker Nancy Pelosi's drug pricing bill (H.R. 3). All 27 Dems voted in favor and all 21 GOP members voted against. More news on: Pfizer Inc., Merck & Co., Inc., Bristol...

A preliminary analysis from the nonpartisan Congressional Budget Office (CBO) found that House Speaker Nancy Pelosi's (D-CA 12th District) bill to lower drug prices would save Medicare $345B between 2023 and 2029 by allowing the Secretary of Health and Human Services to negotiated lower pr...

According to a new report from the nonprofit Institute for Clinical and Economic Review (ICER), AbbVie ( ABBV -0.6% ) and Roche ( OTCQX:RHHBY -1.6% ) were number one and two, respectively, in terms of the impact of their price increases on U.S. drug spending. More news on: AbbVie Inc...

In an interview with CNBC, Health Secretary Alex Azar revealed that the Trump administration is working on a plan that would allow the U.S. to import medicines from Canada, but offered no additional details as to how the plan would work. More news on: ProShares Trust - ProShares Ultra Na...

By a 19-9 vote, the Prescription Drug Pricing Reduction Act has advanced out of the Senate Finance Committee and will go before the full Senate this fall. The bill would cap out-of-pocket costs for medicines at $3,100 per year for Medicare beneficiaries beginning in 2022 and require drug m...